Metabolic Syndrome
Conditions
Keywords
Obesity, Metabolic Syndrome, ENDOBARRIER®
Brief summary
Obesity and metabolic syndrome (MS) are closely interrelated leading to increased mortality, mainly due to cardiovascular disease. In addition, some cancers are much higher when obesity is associated with metabolic syndrome. Bariatric surgery allows significant and sustained weight loss with marked improvement of MS. Considered too invasive, surgery is proposed to a small proportion of patients who could theoretically benefit. The ENDOBARRIER® device implanted endoscopically is an innovative approach developed for management of obesity in the non-surgical manner with benefits for improvement in MS already reported in literature.
Detailed description
Obesity, defined as a body mass index (BMI) over 30 kg / m², has now affected more than 14% of the French population. This condition is associated with several co-morbidities, and increased mortality, mainly due to cardiovascular disease and some cancers. These risks are much higher when obesity is associated with metabolic syndrome. Conventional medical care for metabolic syndrome, even conducted by multidisciplinary teams combining dietary advice, physical activity and psychological treatment offers only limited results, both in weight reduction and comorbidities. Bariatric surgery allows however a significant and sustained weight loss in the majority of cases, and a decrease in the frequency and severity of co-morbidities, including type 2 diabetes, and decreased mortality including cardiovascular. Considered too invasive by many practitioners and patients, surgery is therefore proposed to a small proportion of patients who could theoretically benefit. The results of surgery have, however, validated the principle of the interventional treatment of obesity and its metabolic complications. Different techniques that may replace surgery are currently being developed. Among these new approaches, the most successful is the device endoluminal liner ENDOBARRIER® (GI Dynamics ™, Boston, USA). The ENDOBARRIER® device could represent a major innovation in the non-surgical management of obesity. The benefits of installing the device on the morbidity associated with obesity are reported in the literature: impact on hypertension, diabetes, dyslipidemia and metabolic syndrome as such. This trial will compare in a randomized study the results, tolerance and cost of the interventional therapy with the device ENDOBARRIER® over conventional therapy in French patients with obesity and metabolic syndrome, with or without diabetes. The evaluation of the cost-effectiveness of this device will clarify its role in the strategy for the management of obesity and its comorbidities.
Interventions
DEVICEENDOBARRIER®
This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
Sponsors
Ministry of Health, France
University Hospital, Lille
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Metabolic Syndrome defined by the presence of at least 3 of the 5 factors identified in the harmonization of the definition of metabolic syndrome by the International Diabetes Federation, the American Heart Association and the National Heart, Lung and Blood Institute * BMI \> 30 kg/m2 * The subject must be a candidate for general anesthesia * The subject must be able to understand the options to comply with the requirement of each intervention program. * Non-pregnant female patients must agree to use a reliable method of contraception for 2 years
Exclusion criteria
* Contraindications from the notice of ENDOBARRIER device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of patients without Metabolic Syndrome | 12 month | The primary end point will be the rate of resolution of Metabolic Syndrome at 1 year as measured by frequency of patients without MS at 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The level of insulin resistance | 12 months, 24 months | — |
| Changed in cardiovascular risk assessed by Framingham Risk Score | 12 months, 24 months | — |
| Changed in quality of life | 12 months, 24 months | — |
| Rate of adverse events | 12 months, 24 months | — |
| Changed in waist circumference | 12 months, 24 months | Changed in waist circumference |
| Changed in blood pressure | 12 months, 24 months | Changed in specific metabolic syndrome parameters such blood pressure |
| Changed in blood sugar | 12 months, 24 months | Changed in blood sugar |
| Changed in triglycerides | 12 months, 24 months | Changed in triglycerides |
| Changed in HDL | 12 months, 24 months | Changed in HDL |
| The cost-benefit ratio for each group | 12 months, 24 months | The cost-benefit ratio for each group by evaluating the medical costs in each arm |
Countries
France
Outcome results
None listed